BioWorld

March 5, 2009

View Archived Issues

Vertex Acquires ViroChem in $377M Cash-Stock Deal

Vertex Pharmaceuticals Inc. is buying Canadian drugmaker ViroChem Pharma Inc., a firm specializing in hepatitis C virus (HCV) and HIV drug development, for about $377 million in a cash-and-stock deal. (BioWorld Today) Read More

Issues Facing Biotech, Pharma Converge to Boost M&A Activity

Read More

New Microbicide Shows Promise, Though Occult Infection Puzzling

Read More

Regulus' Coffer Gets Healthy with $20M from Benefactors

Read More

Pharmexa Acquires Affitech, Creating New Antibody Firm

Read More

Other News To Note

Read More

Clinic Roundup

Read More